BR112012009885A2 - "processos diagnósticos para determinação de prognóstico de câncer de pulmão de célula não-pequena" - Google Patents

"processos diagnósticos para determinação de prognóstico de câncer de pulmão de célula não-pequena"

Info

Publication number
BR112012009885A2
BR112012009885A2 BR112012009885A BR112012009885A BR112012009885A2 BR 112012009885 A2 BR112012009885 A2 BR 112012009885A2 BR 112012009885 A BR112012009885 A BR 112012009885A BR 112012009885 A BR112012009885 A BR 112012009885A BR 112012009885 A2 BR112012009885 A2 BR 112012009885A2
Authority
BR
Brazil
Prior art keywords
small cell
lung cancer
cell lung
diagnostic processes
prognosis
Prior art date
Application number
BR112012009885A
Other languages
English (en)
Inventor
Dimitri Seminarov
John S Coon
Ke Zhang
Rick R Lesniewski
Xin Lu
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of BR112012009885A2 publication Critical patent/BR112012009885A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/52—Use of compounds or compositions for colorimetric, spectrophotometric or fluorometric investigation, e.g. use of reagent paper and including single- and multilayer analytical elements
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/112—Disease subtyping, staging or classification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pulmonology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

"processos diagnósticos para determinação de prognóstico de câncer de pulmão de célula não-pequena" são mostrados processos para identificação de pacientes de câncer de pulmão de célula não-pequena de estágio inicial (nsclc) que terão um prognóstico desfavorável para a recorrência de câncer de pulmão após ressecção cirúrgica. os processos são baseados em parte na verificação de que ganhos de número de cópias cromossômicas em chr19, 34,7 mb - 35,6 mb podem ser usados para classificação de prognóstico. os processos preferivelmente usam fluorescência de hibridização in situ com sondas de ácido nucléico marcadas fluorescentemente para hibridização para amostras de pacientes para quantificação de número de cópias cromossômicas deste locus genético, que inclui o gene ciclina e1.
BR112012009885A 2009-10-26 2010-10-25 "processos diagnósticos para determinação de prognóstico de câncer de pulmão de célula não-pequena" BR112012009885A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25495509P 2009-10-26 2009-10-26
PCT/US2010/053900 WO2011056490A1 (en) 2009-10-26 2010-10-25 Diagnostic methods for determining prognosis of non-small cell lung cancer

Publications (1)

Publication Number Publication Date
BR112012009885A2 true BR112012009885A2 (pt) 2016-11-29

Family

ID=43431901

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112012009885A BR112012009885A2 (pt) 2009-10-26 2010-10-25 "processos diagnósticos para determinação de prognóstico de câncer de pulmão de célula não-pequena"

Country Status (14)

Country Link
US (2) US9297045B2 (pt)
EP (2) EP2494071A1 (pt)
JP (3) JP2013507988A (pt)
KR (2) KR101815184B1 (pt)
CN (2) CN105586433A (pt)
AU (1) AU2010315601A1 (pt)
BR (1) BR112012009885A2 (pt)
CA (1) CA2778004C (pt)
IL (1) IL219367A0 (pt)
MX (1) MX2012004907A (pt)
RU (1) RU2012121874A (pt)
TW (1) TW201120449A (pt)
WO (1) WO2011056490A1 (pt)
ZA (1) ZA201203011B (pt)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11149299B2 (en) * 2015-06-25 2021-10-19 Ramesh Vallabhaneni Method and system for multiplex profiling of chromosomes in biological samples using target-specific DNA probes
CN109609636B (zh) * 2018-12-29 2021-11-30 上海交通大学医学院附属瑞金医院 一种肺腺癌差异性表达circRNA的检测试剂盒及其应用
WO2021222816A1 (en) * 2020-05-01 2021-11-04 Cedars-Sinai Medical Center Isolation and functional analysis of epithelial progenitor cells from the human lung
KR20220060198A (ko) * 2020-11-04 2022-05-11 국립암센터 유전자 복제수 변이 정보를 이용하여 췌장암 환자의 생존 예후를 예측하는 방법
KR102565761B1 (ko) 2022-12-08 2023-08-10 한화시스템(주) 주반사경의 플렉셔 마운트 본딩장치
KR102610066B1 (ko) 2023-08-22 2023-12-05 한화시스템(주) 주반사경의 플렉셔 마운트 본딩장치 및 본딩 방법

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5756696A (en) 1986-01-16 1998-05-26 Regents Of The University Of California Compositions for chromosome-specific staining
US5322770A (en) 1989-12-22 1994-06-21 Hoffman-Laroche Inc. Reverse transcription with thermostable DNA polymerases - high temperature reverse transcription
AU622426B2 (en) 1987-12-11 1992-04-09 Abbott Laboratories Assay using template-dependent nucleic acid probe reorganization
KR950013953B1 (ko) 1990-01-26 1995-11-18 애보트 래보라토리즈 리가제 연쇄 반응에 적용가능한 표적 핵산의 증폭 방법
US5491224A (en) 1990-09-20 1996-02-13 Bittner; Michael L. Direct label transaminated DNA probe compositions for chromosome identification and methods for their manufacture
US6174681B1 (en) 1999-03-05 2001-01-16 Mayo Foundation For Medical Education And Research Method and probe set for detecting cancer
EP1362124B1 (en) 2001-02-20 2011-07-06 Vysis, Inc. Methods and probes for the detection of cancer
CN1252283C (zh) 2001-04-30 2006-04-19 关新元 卵巢癌的检测方法和试剂盒
US20060024692A1 (en) 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
GB2411229B (en) 2003-07-22 2006-04-12 Hitachi Int Electric Inc Object tracking method and object tracing apparatus
JP2005304497A (ja) * 2004-03-25 2005-11-04 Joji Inasawa 特定の癌関連遺伝子を用いる癌の検出方法及び癌の抑制方法
EP2527460B1 (en) 2004-05-27 2014-12-24 The Regents of The University of Colorado Methods for prediction of clinical outcome to epidermal growth factor receptor inhibitors by cancer patients
EP2163624A1 (en) 2004-09-24 2010-03-17 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers by tRNA-dihydrouridine synthase activity of URLC8
WO2006128195A2 (en) 2005-05-27 2006-11-30 Dana-Farber Cancer Institute Methods of diagnosing and treating cancer by detection of chromosomal abnormalities
KR100759288B1 (ko) 2005-11-14 2007-09-17 가톨릭대학교 산학협력단 비교유전자보합법을 이용한 폐암 및 폐암의 하부유형 진단방법
US20100292090A1 (en) * 2006-08-25 2010-11-18 Oncotherapy Science, Inc. Prognostic markers and therapeutic targets for lung cancer
WO2008050356A1 (en) 2006-10-27 2008-05-02 Decode Genetics Cancer susceptibility variants on chr8q24.21
BRPI0908173A2 (pt) 2008-02-21 2016-12-06 Basf Se composição para cuidado pessoal, e, método para fabricar uma composição ou uma formulação antimicrobiana para cuidado pessoal
US8951725B2 (en) 2008-04-14 2015-02-10 Abbott Laboratories Diagnostic methods for determining prognosis of non-small cell lung cancer

Also Published As

Publication number Publication date
EP2682482A1 (en) 2014-01-08
KR101815184B1 (ko) 2018-02-05
EP2494071A1 (en) 2012-09-05
CA2778004A1 (en) 2011-05-12
MX2012004907A (es) 2012-06-14
CN102656281B (zh) 2016-04-20
CA2778004C (en) 2018-03-13
KR20120101016A (ko) 2012-09-12
ZA201203011B (en) 2012-12-27
IL219367A0 (en) 2012-06-28
KR20180014059A (ko) 2018-02-07
AU2010315601A1 (en) 2012-05-10
RU2012121874A (ru) 2013-12-10
JP2017136071A (ja) 2017-08-10
JP2013507988A (ja) 2013-03-07
TW201120449A (en) 2011-06-16
WO2011056490A1 (en) 2011-05-12
JP2016105710A (ja) 2016-06-16
US9297045B2 (en) 2016-03-29
CN105586433A (zh) 2016-05-18
CN102656281A (zh) 2012-09-05
US20110130295A1 (en) 2011-06-02
JP6106257B2 (ja) 2017-03-29
US20160160298A1 (en) 2016-06-09

Similar Documents

Publication Publication Date Title
BR112012009879A2 (pt) "métodos diagnósticos para determinar o prognóstico de câncer de pulmão de não pequenos células"
Tsang et al. NanoString, a novel digital color-coded barcode technology: current and future applications in molecular diagnostics
Narrandes et al. Gene expression detection assay for cancer clinical use
ES2741745T3 (es) Método para usar la expresión génica para determinar el pronóstico de cáncer de próstata
Mengual et al. Using microRNA profiling in urine samples to develop a non‐invasive test for bladder cancer
Corbetta et al. Differential expression of microRNAs in human parathyroid carcinomas compared with normal parathyroid tissue
Thomas et al. Expression profiling of cervical cancers in I ndian women at different stages to identify gene signatures during progression of the disease
AU2022209343A1 (en) Methods, compositions, kits and devices for rapid analysis of biological markers
ES2735993T3 (es) Métodos para predecir el resultado clínico del cáncer
Bjaanæs et al. Unique microRNA‐profiles in EGFR‐mutated lung adenocarcinomas
US9249465B2 (en) Molecular markers for lung and colorectal carcinomas
Liu et al. Blood-based liquid biopsy: Insights into early detection and clinical management of lung cancer
TW201638815A (zh) 判定癌症狀態之方法及系統
Chen et al. Comparison of nanostring nCounter® data on FFPE colon cancer samples and Affymetrix microarray data on matched frozen tissues
MX2013013746A (es) Biomarcadores para cancer de pulmon.
BR112012009885A2 (pt) "processos diagnósticos para determinação de prognóstico de câncer de pulmão de célula não-pequena"
Stricker et al. Expression profiling of 519 kinase genes in matched malignant peripheral nerve sheath tumor/plexiform neurofibroma samples is discriminatory and identifies mitotic regulators BUB1B, PBK and NEK2 as overexpressed with transformation
Chiam et al. Identification of microRNA biomarkers of response to neoadjuvant chemoradiotherapy in esophageal adenocarcinoma using next generation sequencing
EP3253891A1 (en) Compositions and methods for determining endometrial cancer prognosis
Magbanua et al. Approaches to isolation and molecular characterization of disseminated tumor cells
Yeung et al. Circulating tumor DNA for mutation detection and identification of mechanisms of resistance in non-small cell lung cancer
Yan et al. Application of non-blood-derived fluid biopsy in monitoring minimal residual diseases of lung cancer
Bratu et al. Tumoral markers in bladder cancer
Xiao et al. Use of two gene panels for prostate cancer diagnosis and patient risk stratification
Chen et al. Prediction of survival of HPV16-negative, p16-negative oral cavity cancer patients using a 13-gene signature: A multicenter study using FFPE samples

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]